Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Basic TA News Snapshot Maps Stats
#21 / 120 Total
BENF - Beneficient - Stock Price Chart
TickerBENF [NASD]
CompanyBeneficient
CountryUSA
IndustryAsset Management
Market Cap104.57MEPS (ttm)-6.88
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S435.69EPS next 5Y-
P/B0.28EPS Q/Q-18893.51%
Dividend-Sales Q/Q-
Insider Own54.58%Inst Own21.27%
Insider Trans0.00%Inst Trans0.83%
Short Float0.29%EarningsNov 13/a
Analyst Recom-Target Price-
Avg Volume232.22K52W Range0.44 - 16.50
Beneficient provides alternative asset, financial and investment services. It offers services to individual investors, wealth advisors, general partners, and institutional investors. The company was founded on June 6, 2023 and is headquartered in Dallas, TX.
OCEA - Ocean Biomedical Inc. - Stock Price Chart
TickerOCEA [NASD, RUT]
CompanyOcean Biomedical Inc.
CountryUSA
IndustryBiotechnology
Market Cap19.08MEPS (ttm)-3.25
P/E-EPS this Y-498.06%
Forward P/E-EPS next Y71.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-3415.71%
Dividend-Sales Q/Q-
Insider Own74.86%Inst Own18.36%
Insider Trans0.00%Inst Trans2.80%
Short Float6.04%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume275.74K52W Range0.62 - 26.60
Dec-05-23 09:45AM EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody (Benzinga)
08:15AM Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody (GlobeNewswire)
Nov-29-23 05:41PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire) -8.95%
Nov-14-23 08:01AM Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics (GlobeNewswire) -15.36%
Nov-01-23 07:00AM Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-31-23 07:00AM Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-26-23 06:30AM EXCLUSIVE: Ocean Biomedical's JV Partner Virion Therapeutics Dosed First Patients In Novel Immunotherapy Study For Chronic Hepatitis B (Benzinga)
05:30AM Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection (PR Newswire)
05:30AM Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection (GlobeNewswire)
Oct-24-23 06:30AM Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis (GlobeNewswire)
Ocean Biomedical, Inc. is a biopharmaceutical company. It engages in the business of discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. The company was founded by Chirinjeev Kathuria in June 2021 and is headquartered in Providence, RI.
TPHS - Trinity Place Holdings Inc - Stock Price Chart
TickerTPHS [AMEX]
CompanyTrinity Place Holdings Inc
CountryUSA
IndustryReal Estate - Development
Market Cap5.73MEPS (ttm)-1.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-53.09%
P/S0.14EPS next 5Y-
P/B-EPS Q/Q-79.77%
Dividend-Sales Q/Q-43.96%
Insider Own16.42%Inst Own53.41%
Insider Trans0.00%Inst Trans-1.46%
Short Float0.28%Earnings-
Analyst Recom-Target Price-
Avg Volume45.47K52W Range0.16 - 0.98
Trinity Place Holdings, Inc. engages in the ownership, investment, management, and development of real estate properties. It also controls a variety of intellectual property assets focused on the consumer sector. The company was founded by Sy Syms in 1959 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Messinger, MatthewPresident and CEOApr 14Buy0.404041602,049,658Apr 14 05:30 PM
Messinger, MatthewPresident and CEOApr 13Buy0.404041622,049,254Apr 14 05:30 PM
Messinger, MatthewPresident and CEOApr 12Buy0.424041702,048,850Apr 13 04:45 PM
Messinger, MatthewPresident and CEOApr 11Buy0.43202872,048,446Apr 13 04:45 PM
Messinger, MatthewPresident and CEOApr 10Buy0.431,0104342,021,700Apr 10 06:53 PM
ROI - RiskOn International Inc - Stock Price Chart
TickerROI [NASD]
CompanyRiskOn International Inc
CountryUSA
IndustryInternet Content & Information
Market Cap0.68MEPS (ttm)-53.26
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y8.17%
P/S11.36EPS next 5Y-
P/B-EPS Q/Q46.14%
Dividend-Sales Q/Q-
Insider Own28.66%Inst Own4.46%
Insider Trans63.66%Inst Trans-33.51%
Short Float4.11%Earnings-
Analyst Recom-Target Price-
Avg Volume347.84K52W Range0.20 - 17.70
RiskOn International, Inc. is a holding company, which is engaged in the operations of oil and gas, financial services, and food freshness management solutions. It operates through the following segments: Financial Services, Technology & Commodities. The company was founded by Randy Scott May on November 19, 2007 and is headquartered in San Antonio, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AULT MILTON C III10% OwnerNov 29Buy0.301,0003004,000Dec 01 04:30 PM
AULT MILTON C III10% OwnerNov 28Buy0.361,000364567,251Nov 29 04:30 PM
AULT MILTON C III10% OwnerNov 27Buy0.351,500525566,251Nov 29 04:30 PM
AULT MILTON C III10% OwnerNov 22Buy0.391,633632564,751Nov 27 04:30 PM
AULT MILTON C III10% OwnerNov 21Buy0.415002053,000Nov 27 04:30 PM
ATXI - Avenue Therapeutics Inc - Stock Price Chart
TickerATXI [NASD]
CompanyAvenue Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.05MEPS (ttm)-1.40
P/E-EPS this Y51.53%
Forward P/E-EPS next Y-
PEG-EPS past 5Y43.30%
P/S-EPS next 5Y-
P/B-EPS Q/Q114.35%
Dividend-Sales Q/Q-
Insider Own45.36%Inst Own3.58%
Insider Trans14.63%Inst Trans15.33%
Short Float2.14%EarningsNov 13/a
Analyst Recom1.00Target Price32.00
Avg Volume1.82M52W Range0.16 - 2.35
Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, a potential alternative that could reduce the use of conventional opioids for patients suffering from acute pain. The company was founded on February 9, 2015 and is headquartered in Bay Harbor Islands, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fortress Biotech, Inc.10% OwnerSep 08Buy0.72418,410301,2551,032,390Sep 12 09:02 AM
ROSENWALD LINDSAY A MDDirectorSep 08Buy0.72348,675251,046354,318Sep 12 09:03 AM
SNES - SenesTech Inc - Stock Price Chart
TickerSNES [NASD]
CompanySenesTech Inc
CountryUSA
IndustrySpecialty Chemicals
Market Cap0.34MEPS (ttm)-67.54
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y48.97%
P/S0.28EPS next 5Y30.00%
P/B0.07EPS Q/Q89.24%
Dividend-Sales Q/Q44.00%
Insider Own10.38%Inst Own1.77%
Insider Trans0.00%Inst Trans-
Short Float2.34%EarningsNov 09/a
Analyst Recom1.00Target Price48.00
Avg Volume187.31K52W Range0.70 - 80.95
SenesTech, Inc. engages in the development and commercialization of proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. It offers its ContraPest product to residential, and commercial sectors such as animal, structural, and food markets. The company was founded by Loretta P. Mayer and Cheryl A. Dyer on July 27, 2004 and is headquartered in Phoenix, AZ.
CONN - Conns Inc - Stock Price Chart
TickerCONN [NASD]
CompanyConns Inc
CountryUSA
IndustrySpecialty Retail
Market Cap62.80MEPS (ttm)-5.68
P/E-EPS this Y-144.33%
Forward P/E-EPS next Y43.66%
PEG-EPS past 5Y-
P/S0.05EPS next 5Y23.00%
P/B0.14EPS Q/Q-1656.85%
Dividend-Sales Q/Q-11.46%
Insider Own45.06%Inst Own28.89%
Insider Trans-0.12%Inst Trans-9.75%
Short Float7.63%EarningsAug 30/b
Analyst Recom2.00Target Price6.25
Avg Volume69.07K52W Range2.91 - 11.69
Conn's, Inc. is a holding company, which engages in the retail and provision of home goods and related services. Its products include furniture, appliances, and consumer electronics. It operates through the Retail and Credit segments. The Retail segment sells home appliances to the retail market, and owns and operates retail stores that offer furniture, home appliances, consumer electronics, and home office accessories. The Credit segment provides in-house consumer credit programs that offer standardized credit decisions, including down payment, limit amounts, and credit terms. The company was founded by Edward Eastham in 1890 and is headquartered in The Woodlands, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stephens Group, LLC10% OwnerJul 19Sale5.0212,77764,1284,217,873Jul 20 05:27 PM
MARTIN DOUGLAS HDirectorDec 27Buy6.354,00025,41564,042Dec 27 06:52 PM
MARTIN DOUGLAS HDirectorDec 23Buy6.477,00045,29460,042Dec 27 06:52 PM
MARTIN DOUGLAS HDirectorDec 22Buy6.251,0006,25047,077Dec 27 06:52 PM
FEAM - 5E Advanced Materials Inc - Stock Price Chart
TickerFEAM [NASD, RUT]
Company5E Advanced Materials Inc
CountryUSA
IndustrySpecialty Chemicals
Market Cap65.48MEPS (ttm)-1.01
P/E-EPS this Y6.19%
Forward P/E-EPS next Y-10.15%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B1.46EPS Q/Q-299.53%
Dividend-Sales Q/Q-
Insider Own31.43%Inst Own20.49%
Insider Trans0.07%Inst Trans22.19%
Short Float11.13%EarningsNov 09/a
Analyst Recom2.50Target Price5.17
Avg Volume141.97K52W Range1.59 - 12.04
5E Advanced Materials, Inc. is an exploration stage company, which engages in the provision of boron and lithium properties in Australia and the United States. It focuses on supplying boron specialty materials, complemented by lithium co-product production. The company was founded on September 23, 2021, and is headquartered in Hesperia, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairchild GeorgePrincipal Accounting OfficerSep 01Option Exercise0.001,22501,225Sep 06 04:27 PM
SALISBURY DAVID JDirectorJun 09Buy3.964,95519,6177,286Jun 12 05:55 PM
vant Hoff GrahamDirectorJun 07Buy3.854,25016,3844,250Jun 07 04:05 PM
VLD - Velo3D Inc - Stock Price Chart
TickerVLD [NYSE, RUT]
CompanyVelo3D Inc
CountryUSA
IndustryComputer Hardware
Market Cap167.32MEPS (ttm)-0.29
P/E-EPS this Y-13.82%
Forward P/E-EPS next Y42.14%
PEG-EPS past 5Y-
P/S1.59EPS next 5Y17.00%
P/B1.53EPS Q/Q78.31%
Dividend-Sales Q/Q24.55%
Insider Own49.85%Inst Own21.35%
Insider Trans-0.30%Inst Trans3.42%
Short Float15.85%EarningsNov 06/a
Analyst Recom1.33Target Price1.86
Avg Volume1.80M52W Range0.88 - 3.95
Velo3D, Inc. operates as technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer, sapphire XC, and SupportFree process. The company was founded by Benyamin Buller in June 2014 and is headquartered Campbell, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Buller BenyaminChief Executive OfficerDec 01Option Exercise0.1810,0001,8005,202,706Dec 05 06:10 PM
Buller BenyaminChief Executive OfficerDec 01Sale1.0012,00011,9475,190,706Dec 05 06:10 PM
Youssef RenetteChief Marketing OfficerNov 21Sale1.0482,32185,68288,861Nov 24 07:00 PM
Buller BenyaminChief Executive OfficerNov 21Sale1.1269,81678,2645,192,706Nov 24 06:54 PM
Chung BernardActing Chief Financial OfficerNov 21Sale1.1211,34312,716194,259Nov 24 06:57 PM
ALLR - Allarity Therapeutics Inc - Stock Price Chart
TickerALLR [NASD]
CompanyAllarity Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap2.04MEPS (ttm)-526.86
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q99.76%
Dividend-Sales Q/Q-
Insider Own1.29%Inst Own16.50%
Insider Trans0.00%Inst Trans-45.84%
Short Float4.60%Earnings-
Analyst Recom1.00Target Price8.00
Avg Volume1.29M52W Range0.45 - 1890.00
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
123456781012